Introduction
Monogenic disorders arise from single causative mutations with high penetrance. adhering to Mendelian inheritance, numerous causative mutations have been discovered that are rare because of negative evolutionary selection pressures. In contrast, common diseases including cardiovascular and CNS disorders, diabetes, cancer, and immune disorders, present complex phenotypes and are considered polygenic. Despite a complex genetic architecture, population and sibling studies have demonstrated a rather high degree of heritability, for example ~50 % of disease risk for coronary artery disease and 80 % for autism is attributed to Abstract Genetic factors strongly influence risk of common human diseases and treatment outcomes but the causative variants remain largely unknown; this gap has been called the 'missing heritability'. we propose several hypotheses that in combination have the potential to narrow the gap. First, given a multi-stage path from wellness to disease, we propose that common variants under positive evolutionary selection represent normal variation and gate the transition between wellness and an 'off-well' state, revealing adaptations to changing environmental conditions. In contrast, genome-wide association studies (GwaS) focus on deleterious variants conveying disease risk, accelerating the path from off-well to illness and finally specific diseases, while common 'normal' variants remain hidden in the noise. Second, epistasis (dynamic genetic factors (Table 1) . Similarly, estimates of heritability in drug treatment outcomes also reveal strong genetic influence (Marshall et al. 2013) , often less well defined because of a paucity of studies involving suitably designed drug trials (examples in Table 1 ). Both for medical management of disease and for guiding optimal drug therapy, understanding the full complement of genetic factors contributing to disease risk and treatment outcomes has potential for profound improvements in health care. Yet, the genomics of complex phenotypes remains unresolved, with known genetic factors accounting for only a small portion of the estimated heritability. Termed the 'missing heritability' (Klein and Zanger 2013; Manolio et al. 2009; Sadee 2012) , this critical gap in our knowledge continues to challenge the tremendous efforts made in genomics medicine. This review analyzes current hypotheses and methodologies designed to narrow the gap, emphasizing new concepts that could overcome the impasse.
What is the 'missing heritability'?
Heritability is reflected by the tendency for offspring to be of similar phenotype as their parents, estimating the impact of genetics on the phenotype. Heritability can be defined as the fraction of phenotype variability in the population that can be accounted for by the genotype. Heritability is usually measured as either broad-sense heritability (H 2 ) or narrow-sense heritability (h 2 ). Both H 2 and h 2 quantify the relative variability (conditional variance) of a phenotype given a genotype. h 2 includes only the additive effects of individual alleles on the phenotype (Zuk et al. 2012) . It has been favored because it is computationally more readily feasible and statistically meaningful in the context of genome-wide association studies (GwaS) (Ruderfer et al. 2013) . On the other hand, measuring heritability as H 2 accounts for gene-gene interactions (epistasis) and epigenetic effects, likely to play a significant role in human health and disease as discussed further below. as noted by Zuk et al., there is a fundamental gap between the estimated heritability (from sibling studies) and that calculated based on known genetic variants. One of the contributing factors for this phenomenon is epistasis, which has been proven in theory to account for a portion of this gap (and termed by Zuk et al. as phantom heritability) . Numerous genes have been associated with complex disorders by targeting single candidate genes, but most display low penetrance and fall far short of accounting for the estimated heritability. with advent of GwaS, large numbers of SNPs are now tested for an effect on disease risk, raising high expectations that we will soon close the gap. while GwaS continue to be successful in revealing candidate genes and pathways, even the combined effect size of all significant SNPs barely exceeds 20 % of population heritability estimates, using additive models (CrossDisorder Group of the Psychiatric Genomics and Genetic Risk Outcome of Psychosis 2013; ehret et al. 2012; Ruderfer et al. 2013) . Initially considered bias-free, the early GwaS design nevertheless relied on haplotype-tagging SNPs (under the assumption these would accurately represent rather frequent causative variants) with variable coverage of genomic regions, favoring protein-coding gene loci. (Leabman et al. 2005) Following the surprisingly limited success of early GwaS, subsequent studies employed SNP chips of much enhanced density (1-5 million SNPs) to cover broadly genomic variation across multiple ethnic populations, with study cohorts of ever increasing numbers of subjects. added to this are imputed variants not covered in the chips but available from large-scale human genome sequencing projects. Predictably, this approach led to discovery of numerous additional risk genes, including rare variants. while these additional variants have narrowed the gap-the overall challenge remains largely unmet.
Why does GWAS fail to close the gap?
GwaS and other genome-wide studies demand extensive corrections for multiple hypotheses testing (Bonferonicorrected significance levels are around p ~ 10
), leaving numerous variants with small individual effects or insufficient frequency hidden in the noise. Moreover, the vast majority of GwaS SNPs are markers while the causative variants remain largely unknown. Further advances have been made with use of polygenic models, and mutational load analyses capturing the effect of rare variants, leading to substantially higher estimates of overall heritability (Keller et al. 2012; Lubke et al. 2012) . However, these models operate under a singular assumption: the genetic effects are additive. we will argue here that this assumption may well be correct for deleterious variants conveying disease risk. Yet, adaptive processes result in frequent variants as a response to environmental conditions, with dynamic gene-gene interactions (epistasis) a main factor in evolution (de visser et al. 2011; Hemani et al. 2013; Imielinski and Belta 2010; wittkopp and Kalay 2012) . Such adaptive variants can turn deleterious under unfavorable conditions but remain in the noise of GwaS results (Gauderman et al. 2013; Hu et al. 2011; Moore et al. 2006; van Hulle et al. 2013) . we address these issues in the context of a multistage disease model that can expand the interpretation of genomics data.
A multi-stage disease model: a concept with potential of narrowing the heritability gap
To address the issue of missing heritability, we propose a multi-stage model that leads to disease. It is our hypothesis that the process begins with the state of well-being and progresses to off-well, and then to illness and finally disease (Fig. 1) . These states are essentially distinct: the off-well state is a subclinical phenotype, while illness is clinically detectable but not well defined, and disease represents a well-defined, clinically measurable state. Different types of genetic variants are likely to play key roles in each of the transitions between these states. The transition from well-being to off-well is a critical initial step in the path towards common multigenic disorders. Here, evolution enables adaptation to environmental changes, maintaining an individual's well-being and reproductive advantage. Positive selection of regulatory variants in epistasis is likely germane in coping with environmental conditions, by establishing low and high activity alleles in the population. we expect these 'normal' variants and their interactions not to pose a strong disease risk per se, and given the stringent criteria of GwaS, to fall under the detection threshold. Yet, several low or high activity alleles in a given pathway (or in multiple pathways) could cause an imbalance that accelerates the transitions to off-well and eventually disease-or conversely, they could be protective favoring a state of well-being. In addition, changes in the environment can reveal deleterious properties of 'normal' variants, as does exposure to modern drugs-leading to unexpected toxicities (Phillips et al. 2001 ) and lack of efficacy. while we consider common variants as critical for the early stages of the process, less frequent deleterious variants are likely the main culprits in determining the path towards specific diseases. Therefore, diverse common disorders often share common risk factors (cross-disorder Fig. 1 Schematics of multi-stage progression from wellness to disease. we hypothesize that frequent 'normal' variant-often under positive selection-represents critical adaptations to environmental changes, and hence do not convey disease risk per se. However, summation of high or low activity variants in a given pathway, together with unfavorable environmental stress, can turn these variants into deleterious risk factors, primarily acting on the transition from wellness to off-well. In contrast, deleterious rare variants may play a key role in guiding the path toward specific diseases. environmental factors and life style further interact dynamically with genetic variants and in particular generate epigenetic marks that are modified by regulatory variants (Heinz et al. 2013; Kilpinen et al. 2013; Mcvicker et al. 2013; Ziller et al. 2013) , thereby linking genetics and epigenetics. The initial transition may be reversible but upon progression to disease the process becomes increasingly irreversible, consistent with the finding that most drug therapy is palliative but not curative when applied at a late stage group CNS 2013) that could play a role in early stages, while also being associated with disease-specific deleterious risk alleles.
In the context of wellness, we may further consider the influence of canalization, first conceptualized by waddington (1942) , to account for robustness during development with similar outcomes regardless of variations in genetic or environmental variations. Such canalization may in part be maintained by epigenetic processes and epistatic interactions, under stabilizing selection (Bergman and Siegal 2003) . Further, increasing complexity of a biological or genetic network tends to show increasing robustness, including capacitors such as the heat-shock protein HSP90 that mask genetic variation. Only substantial genetic or environmental deviations thus are expected to disturb the wellness state, the phenotype of highest complexity integrating multiple smaller phenotypic modules ("endophenotypes"). It is perhaps telling that the vast majority of significant GwaS hits relates to such endophenotypes (e.g., lipid levels) rather than directly to disease risk. as a result, we may rethink the role of epistasis as having evolved to maintain wellness, with loss of epistasis a critical event in the transition to "off-well". This hypothesis has relevance to the type of analyses suitable for retrieving information inherent to GwaS data.
A role for rare variants in disease risk
applied to ever larger subject cohorts, GwaS is beginning to reveal the contributions of rare SNPs (≪1 % Ma) as disease risk factors (Keller et al. 2012; Liu and Leal 2012) ; however, the combined effects of rare variants also account only for a small portion of overall heritability. In some cases these variants may have only negligible impact (Hunt et al. 2013) ; moreover, population stratification may confound rare variant associations (O'Connor et al. 2013) .
GwaS focuses on SNPs whereas other variants can also contribute to disease risk, such as indels (insertion-deletion) and copy number variants (CNv). all types of variants are detectable with use of next-generation sequencing methodology. with a focus on rare variants, large clinical cohorts must be sequenced to attain statistical significance. as a result, currently available data are mainly based on exome sequencing as whole-genome sequencing has only recently become feasible on a large scale. exome sequencing has proven successful in revealing candidate genes carrying mutations deemed deleterious from bioinformatics analyses. However, exome sequencing has focused on protein-coding exons representing only a small portion of the genome, and therefore, interpretation of the results must reflect ascertainment bias. For example, exome analysis of 2,536 cases and 2,543 controls (van Dongen and Boomsma 2013) finds enrichment of rare variants in schizophrenia candidate genes affecting synaptic functions and related pathways, demonstrating a mutational burden across numerous genes as a contributing factor (Purcell et al. 2014 ). However, the combined effect size of rare and moderately frequent SNPs (0.5-1 %), and rare CNvs, was 6-7 % of overall risk. Therefore, these results cannot fill the heritability gap but provide critical information on candidate genes and pathways. a companion paper by Fromer et al. applied exome sequencing to 623 schizophrenia trios (mother, father, and affected offspring), enabling the detection of de novo mutations, which occur at a frequency of ~10 −8 per base (Keightley 2012) . The results corroborate the importance of very rare variants and specifically CNvs associated with increased risk. Schizophrenia reduces reproductive success, but maintains a population frequency of ~1 %; yet, all rare de novo mutations combined do not account for high schizophrenia prevalence in the face of substantial reproductive deficiency associated with schizophrenia (van Dongen and Boomsma 2013). Keightley has proposed that new deleterious mutations may be tolerated if selection acts on relative fitness differences between individuals or if there is synergistic epistasis (Keightley 2012) , possibly in the context of stabilizing selection. Therefore, we conclude that other genetic risk factors play a critical role in defining disease risk. It is also worth noting that few of the risk genes serve as drug targets, with exceptions in targeted cancer therapies. Genes affecting biogenic amine signaling are common drug targets, and some of these genes carry frequent regulatory variants (Table 2) , likely affecting early stages of disease progression ( Fig. 1 ), but not scoring significantly in GwaS. as a consequence, therapy of full-blown disease is symptomatic and palliative rather than curative, whereas early intervention could prevent or reverse disease progression. Predicting disease risk and optimal type of therapy, therefore, has the potential for substantial improvements in health care (Pierce et al. 2013) .
we have performed a GwaS survey to ask whether drug targets, or drug-related genes, indeed fail to be enriched with significant GwaS hits compared to other genes. among the currently 1,300 drug targets (Law et al. 2014) , ~500 genes are implicated in GwaS indexed by the NHGRI GwaS Catalog, with most related to endophenotypes rather than directly to disease risk (Hindorff et al. 2014) . In comparison, ~50 % of all protein-coding genes are GwaS hits (Hindorff et al. 2014) , with a similar distribution between endophenotypes and disease risk. It is at first glance remarkable that the drug targets are not prevalent in this list; however, if one considers the hypothesis illustrated in Fig. 1 , drug targets may be most relevant at the interface between wellness and "off well", thereby accounting for lack of GwaS enrichment. Table 2 List of genes with frequent regulatory variants identified with use of allelic mRNa ratio analysis and molecular genetics studies Note that srSNPs (structural RNa vaiants) and rSNPs (regulatory variants) are approximately equal in number; whether this relationship can be extrapolated to non-coding RNas remains to be determined. The GwaS column provides a summary of current significant GwaS hits associated with each gene as indexed by the NHGRI GwaS Catalog (Hindorff et al. 2014) . Few associations are with disease risk directly, whereas other biomarkers such as lipid levels, and pharmacological phenotypes are well represented earlier, we have discussed canalization as a process that enhances robustness of a complex network. applied to drug therapy, one can view the desired response as reversing genetic and environmental deviation that have overcome the canalization hurdle and have led to the path towards illness. For example, statins block HMGCoa reductase (HMGCR) and reliably lower cholesterol levels (the endophenotype), thereby reducing the risk for myocardial infarction. However, only less that 50 % of patients are protected from suffering MI (Neyt et al. 2009 ), as more pathways to disease exist that are unaffected by statins. Conversely, drugs also act as the environmental insult leading to adverse drug reactions, still a leading cause of morbidity and mortality (Phillips et al. 2001) . Temperature regulation in warmblooded animals is an example of strict canalization, with body temperatures kept within a very small range, resistant to multiple environmental and genetic variation. Yet, certain drugs targeting the serotonin system such as antidepressants can cause a 'serotonin syndrome'-in particular in subjects with interacting genetic mutations including drug-metabolizing enzymes-characterized by dysregulation of body temperature as a main symptom (Kreuzer et al. 2012) . Clearly, drugs can disturb the 'canalized' equilibrium sufficiently to cause overt toxicity. Understanding the underlying causes will help reduce the incidence of therapy failures.
Evidence for the presence of frequent regulatory variants in key candidate genes
The early GwaS goal to discover frequent variants conveying risk for common disorders led to the realization that common SNPs typically have low effect size. we propose that common regulatory variants (largely outside the protein-coding exome) can have robust effects expressing low and high activity version of the encoded proteins in the 'normal' range-failing to register in GwaS as risk alleles per se. To test for the presence of frequent regulatory variants in critical candidate genes, many of which serve as drug targets or mediate drug effect pathways, we have undertaken a systematic molecular genetics study of over 200 genes. Listed in Table 2 , and discussed in more detail further below, key genes serving as drug targets are enriched with frequent regulatory variants, whereas this is a rare occurrence in other genes tested. Generating low and high activity alleles, with significant phenotype associations, these variants affect disease risk only moderately, and therefore, GwaS signals are weak. Possibly, the interactions between this type of frequent 'normal' variants among each other and with rare variants, and with the environment, afford either protection or risk of transiting to offwell and then to illness and disease.
we now focus on four questions that require resolution: what are the causative variants and how do they act; what is the impact of distinct RNa classes; what is the role of dynamic interactions between variants (epistasis) in complex phenotypes; how do evolutionary selection pressures affect the genetic architecture of complex phenotypes.
The nature of genetic variants affecting cell biology
while SNPs are abundant, other types of genetic variation also contribute to variability of the genome (small insertions and deletions, copy number variants, inversions and translocations, and chromosomal abnormalities). early work has focused on nonsynonymous SNPs in proteincoding regions (coding SNPs or cSNPs), as these are easily detected and can be studied in vitro in cell cultures. However, GwaS analyses have revealed that only 9 % of significant associations are contributed by cSNPs, while synonymous SNPs contribute 2 % ). The latter are distinct targets of evolutionary selection pressures as the wobble codon can evolve to generate favorable RNa conformations that affect RNa biology and stability without altering the protein sequence (Shabalina et al. 2006) . effect size of human disease associations was found to be similar for synonymous and nonsynonymous SNPs (Chen et al. 2010) . an additional 2 % of GwaS-significant variants reside in 3′ and 5′ UTRs, altering mRNa processing, turnover, trafficking, and translation. The remaining 87-88 % are intronic or intergenic and presumed to be regulatory, mostly affecting transcription of protein-coding genes while intronic SNPs can also affect RNa processing ).
Sequencing of the human genome and extensive annotations of putative functions across the entire genome, provided in eNCODe (Consortium et al. 2012; Gerstein et al. 2012; Zhang et al. 2007) , have revealed that only 1.2 % of the human genome encodes mRNa exons that translate into proteins. It is also now clear that countless regulatory elements are dispersed across the entire genomic sequence, characterized by epigenetic markers (e.g., CpG islands and histone modifications). Regulatory elements are enriched with significant GwaS SNPs (Khurana et al. 2013; Kindt et al. 2013; Paul et al. 2013; Pennisi 2011; Sadee 2009; Zou et al. 2012) , demonstrating their relevance in affecting phenotype. In addition, ~75 % of the genome is transcribed into non-coding RNas that serve numerous functions, substantially broadening the definition of what is considered a gene.
These findings lead to a new definition of the types of functional genetic variants we encounter in the human genome. as a majority of variants are single-nucleotide polymorphisms (SNPs), we adopt 'SNPs' in the following classification of functional genetic variants (Fig. 2) First, nonsynonymous coding SNPs and equivalent variants (cSNPs) alter protein sequence and function. Second, regulatory variants or rSNPs affect transcription of protein-coding genes, and additionally of the large number of non-coding RNas (Cawley et al. 2004 ). Since the number of annotated non-coding RNas continues to rise and now exceeds ~35,000, the potential for GwaS-significant rSNPs is tremendous. Third, we consider all variants in expressed RNas (introns and exons, coding and non-coding) to have the potential to alter RNa functions through conformational and primary structure changes affecting stability and interactions with proteins, RNas, and small substrates. analyses of RNa folding dynamics have revealed that ~90 % of all SNPs in single-stranded RNas, including mRNa, alter the RNa folding assembly, thereby potentially altering the RNa's functions . we have termed these variants structural RNa SNPs, or srSNPs ( Fig. 2) . Since possibly up to 75 % of the human genome is detectably transcribed, the mutational potential of srSNPs is vast. In some cases, even nonsynonymous cSNPs act as srSNPs rather than, or in addition to, affecting protein function. For example, we had demonstrated that the nonsynonymous 118A>G variant (rs1799971) in the mu-opioid receptor OPRM1 lowers RNa processing and translation, thereby causing a defect in the receptor's expression (Table 2) (Zhang et al. 2005 )-hence OPRM1 118A>G can be considered an srSNP. Similarly, SNPs that alter exonic enhancer elements in coding regions are srSNPs, such as rs7305115 in TPH2, encoding tryptophan hydroxylase (Lim et al. 2007 ). also, exonic codons can serve as transcription factor binding sites (the duon hypothesis) thereby affecting protein evolution (Stergachis et al. 2013) . These examples illustrate that long-held functional definitions require ongoing revision to guide investigations into molecular genetics mechanisms.
even if a single variant in an RNa fails to alter function appreciably, it nevertheless opens new avenues for evolving new functions with the addition of further variants in the same RNa, broadening evolvability at the level of RNa biology (Draghi et al. 2010) . Therefore, one must consider whether a variant anywhere in the genome serves as an rSNP or a srSNP-the latter type having received much too little attention. Resolving these questions will be essential as the molecular genetic mechanisms must be properly understood to gain a better appreciation of the underlying biology and pathophysiology.
Distinct classes of RNAs and their interactions
with the discovery of an increasing number of non-coding RNas (Hangauer et al. 2013) , the question of their biological functions has become paramount to cell biology (Blower et al. 2007; Djebali et al. 2012; Gamazon et al. 2013; Kim et al. 2010; Kosik 2013; Kowalczyk et al. 2012; Salmena et al. 2011) . as much as single-stranded RNas fold up upon themselves, generating structures critical to their functions, for example interactions with proteins, they are also likely to interact among each other, and with genomic DNa sequences (Dethoff et al. 2012 ). Because of distinct functions and of operational considerations in performing RNaseq analyses with next-generation sequencing, we divide RNas into protein-coding RNas and small (<200 bases) and large (>200 bases) non-coding RNas, many of which are not polyadenylated. Recent studies document that these RNa classes interact with each other (Fig. 3) , and therefore, systems biology strategies need to Fig. 2 Genetic variants classified by function. The term SNP as used here represents any type of variant, including variable repeats, CNvs, indels, and more. srSNPs can affect splicing and hence protein structure as well. with ~75 % of the human genome transcribed, srSNPs have vast potential to affect cell biology Fig. 3 whole transcriptomes include many classes of RNas forming interconnected networks that remain largely unknown. Use of nextgeneration sequencing enables measurements of short and long RNas (currently, short RNas such as microRNas require separate preparation for sequencing), and RNa isoforms generated at each gene locus (variable transcription start and polyadenylation sites, splice isoforms, etc.). Long ncRNas include antisense ncRNa, enhancer ncRNa (eRNa and meRNa), pseudogene ncRNa, intergenic ncRNa, and 3′UTR ncRNa. Precursors to short RNas are detected by RNaseq in the long RNa fractions; they give rise to miRNa, snoRNa, snRNa, piRNa, tRNa (Kowalczyk et al. 2012) . srSNPs affect all RNa classes, are rarely found in the mature short RNas, but rather have potential to alter precursor RNa processing. Direct effects on translation are limited to protein-coding mRNas reflect all RNa classes. Long non-coding RNas (lncRNas) include intergenic lnRNas that are capable of targeting a complementary sequence in genomic DNa while pulling along epigenetic protein factors that mark this specific site of the chromatin (Guttman and Rinn 2012) . Further classes include circular RNas (mostly derived from introns) that sequester microRNas, snoRNa, ribosomal RNas, and microRNa precursors, to name a few (Kowalczyk et al. 2012; Rogelj 2006; Salmena et al. 2011) . among the short non-coding RNas, microRNas have been under intense study because of their capacity to bind to numerous target sites on mRNas, thereby preventing translation or destroying the mRNa; however, microRNas are also interacting with non-coding RNas, for example circRNas that serve as sponges by binding multiple microRNa copies (Kosik 2013) . Polymorphisms in microRNa target sites can have dramatic effects on protein expression and downstream phenotypes (Gamazon et al. 2013 ). These pervasive interactions likely contribute to the presence of numerous highly conserved segments of gDNa in regions previously considered to be of no obvious significance, and they highlight the relevance of srSNPs by affecting interactions among RNas and proteins-a complex network still barely understood.
Incorporating dynamic gene-gene-environment interactions in association studies
Numerous studies document a pervasive role of epistasisinitially defined to indicate instances where a genetic variant has little effect per se but can turn deleterious or beneficial for a phenotypic trait in the presence of a second mutation (Baurley and Conti 2013; Hemani et al. 2013) . New computational and statistical approaches are being developed to detect and measure epistasis in GwaS (Gauderman et al. 2013; Hu et al. 2011; Moore et al. 2006; van Hulle et al. 2013 ). More broadly, any non-linear gene-gene interaction, or interactions between distinct variants in the same gene, can be considered epistasis-likely occurring with additional modulation by environmental stimuli (Kaprio 2012; van Hulle et al. 2013) , including drugs. an example from our group involves an interaction between variants in DRD2 encoding the dopamine D2 receptor and DAT encoding the dopamine transporter, the main target of cocaine Zhang et al. 2007 ). we had identified several regulatory variants in both (Table 2) , and because DRD2 and DaT proteins physically interact presynaptically, we searched for epistatic effects. while a DRD2 splicing SNP increased lethal risk of cocaine abuse nearly threefold, and none of the DAT variants had a significant main effect per se, a DRD2/DAT variant interaction conveyed a 7-8 fold risk epistatically whereas another DRD2/DAT variant interaction offset the increased risk entirely )-an example of a genegene-environment (drug) interaction. Hence, the effects of a deleterious mutation can be alleviated by another variant, a scenario relevant to Mendelian (monogenic) disorders where penetrance of a single causative mutation can vary between carriers because of varying genetic background (Hershberger et al. 2013 ).
epistatic interactions have been shown to contribute to quantitative traits such as gene expression and lipid levels as well as disease risk, for example in relation to diabetes and alzheimer's disease (Gusareva et al. 2014; Hemani et al. 2014; Lopez-Rios et al. 2011; Ma et al. 2014) . Furthermore, epistasis has been proposed as one of the mechanisms to fill the heritability gap (wang et al. 2012b; Zuk et al. 2012 ). Yet, attempts to study epistasis in GwaS have met with limited success at best, leading to the view that it plays but a minor role. However, computational simulations indicate that the use of surrogate markers rather than causative variants rapidly degrades a signal of epistasis, because of error penalties when both variants tested for epistasis fail to fully represent the true genetic component of each gene (Hemani et al. 2013 ). This obstacle is compounded by the steeply increased burden of multiple hypotheses testing when evaluating all possible SNP-SNP combinations in GwaS. Given sufficiently large study cohorts, it should nevertheless be possible to probe epistasis broadly (Kooperberg and Leblanc 2008) . Indeed, a recent study involving the large wellcome Trust cohort on several common disorders provides a fist glimpse of epistasis on this scale (Lippert et al. 2013) . Performing a complete analysis of all possible SNP-SNP interactions and setting a genome-wide significance level of p = 10
, a substantial number of epistatic SNP pairs were detected. Importantly, using a liberal threshold p value of 10 −6 to select candidate SNPs for the interaction study would have missed all of the significant epistatic interactions, suggesting that variants deeply buried in the noise have potential of contributing to disease risk under epistasis. This result supports the view that epistasis could play a key role in understanding the genetics of complex traits.
Quantitative analysis reveals that genetic models incorporating epistatic interactions rather than additive effects have the potential to yield better predictors of treatments outcomes, relevant to biomarker development. Consider two alternative models for adverse-event risk in drug treatments, both with the same population average risk and the same degree of heritability. In the first, additive model, two unlinked variants each contribute independently to the risk. In the second, epistatic model, carriers of both variants suffer an increased risk as a result of epistatic interactions, with the same population variance in the total effect size (equaling the broad-sense heritability H 2 ). In either case, avoiding treatment for carriers of both variants will reduce the total number of adverse events, but the reduction is greater for the epistatic model. even though the two models assume the same contribution to the broad-sense heritability H 2 , the epistatic model identifies a greater portion of treated subjects at risk of adverse events. This example illustrates a general property-large effect sizes on smaller portions of the population are, given the same total heritability, more useful in identifying populations at high or low risk-an outcome GwaS approaches have so far failed to replicate. Thus, effects arising from epistatic interactions are worth pursuing, because they can enhance predictive power for disease risk or treatment outcomes.
Understanding the evolutionary history of human genetic variation, including epistasis
Genetic variation arises at random and can disseminate through a population at random (genetic drift), if deleterious it may undergo purifying selection, or it may be subject to positive selection by conveying reproductive advantages, along several proposed fitness models (van Dongen and Boomsma 2013) . Keeping with the main topic of this review, we focus on frequent variants under positive selection. Such variants carry a signature of being more frequent on longer haplotypes than expected from genetic drift or bottleneck population scenarios. They can be identified by several algorithms, including the composite multiple signals (CMS) test (Grossman et al. 2013) . variants under evolutionary selection must have sufficient phenotypic impact to be selectable by conveying an overall reproductive advantage, but may nevertheless contribute to disease risk, under unfavorable environmental conditions, or in the presence of additional interacting variants, or both. Often, a selectable variant can rapidly accumulate in a population as heterozygous carriers have an advantage, for example protection against malaria by mutations in hemoglobin genes (williams et al. 2005) . This scenario leads to balancing selection, with minor allele frequencies leveling off at a stable level. a search for variants maintained over long evolutionary times via balancing selection, common to humans and chimpanzees, revealed an unexpectedly large number, most of which outside protein-coding exons and hence likely having regulatory functions (Leffler et al. 2013) . Mimicking this favored state in heterozygous carriers, a second mutation in the same gene might then accumulate under purifying selection over a much longer time period if the favored state is now realized in homozygous carriers. Hence, we can expect different types of frequent variant to occur in genes undergoing positive selection, some with high and others with low to intermediate allele frequency, many positioned on distinct long haplotypes, a possible signature of positive selection. we find more than one frequent regulatory variant in a number of clinically relevant genes, including CETP, CHRNA4, CYP2D6, and DRD2 (see Table 2 ). Combinations of causative variants are critical for assessing full effect size or risk in GwaS analyses and strongly confound the interpretation of a gene's impact if neglected.
Strong evidence further stipulates that gene regulation is a preferred pathway undergoing evolutionary selection pressure (Leffler et al. 2013; Shinar and Feinberg 2010; ward and Kellis 2012; wittkopp and Kalay 2012) , with protein abundance a primary selectable target (Khan et al. 2013; wu et al. 2013) . we consider here both rSNPs and srSNPs to represent regulatory functions, although srSNPs could also have structural impact, or interfere with catalytic and sensory RNa mechanisms (ribozymes, ribo-switches, etc.). as regulatory processes are highly tissue selective, and each tissue has distinct requirements related to optimal gene properties, a regulatory variant can be selected to affect gene expression favorably in one tissue without any effect on other tissues-examples include CETP (Papp et al. 2012) and CYP3A4 (wang et al. 2011a) , with variant effects dominantly in the liver but lacking in other tissues. as a result, favorable variants can evolve with targeted effect on select body functions. The activity of such variants can fall into the normal range and affect specific physiological functions, therefore, conveying little disease risk per se and escaping GwaS detection.
Much research further supports the notion that genegene interactions play a pervasive role in evolution, either by mitigating the deleterious effects (stabilizing selection) of a mutation or promoting new favorable traits (de visser et al. 2011; Imielinski and Belta 2010; Lehner 2011; Shinar and Feinberg 2010; watt 2013; wittkopp and Kalay 2012) . Rather than being selectable on their own, genetic variants appear to evolve under interactive dynamics, evidenced at the level of RNa and protein expression or function (de visser et al. 2011; Khan et al. 2013) . Protein-protein interactions are critical to cell biology, and changes in protein sequence are under epistatic constraints (Breen et al. 2012; weinreich and Knies 2013 ). This appears also to be the case for RNas that communicate among each other driving structural epistasis or forming interacting networks Dutheil et al. 2010; Guttman and Rinn 2012; Kowalczyk et al. 2012 )-possibly a fundamental process that maintains large portions of the human genome under strict conservations. we can therefore entertain the hypothesis that regulatory variants under positive selection are most likely to display epistasis with interacting partners. applied to GwaS, we need to focus on variants carrying a signature of positive selection (Grossman et al. 2013 ) when searching for epistasis as a contributor to overall heritability of a complex phenotype. as noted by Zuk et al. 2012, epistasis may account for gaps in estimating heritability of complex disorders from GwaS data.
Gene-gene-environment interactions and drug response
adaptation to the environment is a principal driver of the evolutionary processes discussed in the previous paragraphs. Obvious factors include climate, nutrient supply, and toxic compounds. In addition, owing to the human population explosion, civilization structures and culture likely play a key role, contributing to unique human traits, such as cognitive functions, communication, and sociability. Genetic adaptations of the innate immune system are further examples of evolutionary pressures from increasing density of human cohabitation in compounds, villages, and cities, as a result of increased risk of infections such as tuberculosis (azad et al. 2012 ). Upregulation of innate immune genes conveys increased resistance but also ramps up autoimmunity, thereby, enhancing risk of common disorders typical of current societies, e.g., diabetes, rheumatoid arthritis, and other inflammatory disorders. How external drivers affect positive selection for behavioral traits at the level of the individual remains to be clarified but key CNS genes show signatures of positive selection, such as MAOA (Pinsonneault et al. 2006) . whether evolutionary selection also proceeds at the population level remains controversial (wilson 1975) , but a range of 'normal' cognitive and emotional traits may be advantageous to a society for coping with a changing environment. None of these variants would be expected to cause strong disease risk, but in combination, several variants conveying all low or high activity in a given pathway could carry strong risk.
Defense against external toxins and xenobiotics has triggered selection of metabolizing enzymes and solute carriers that protect the body against external assault. For instance, the liver is loaded with members of the cytochrome P450 (CYP) enzyme family, each with varying substrate specificity. Some display rather broad substrate affinities and are most abundant, such as CYP3a4; these enzymes are probably under mutual selection pressures. Indeed, we have found very long frequent haplotypes in the CYP2D6 gene locus, containing enhancer variants >100 kb downstream, with the minor alleles increasing transcription substantially (wang et al. 2014) . Similarly, an intronic SNP in CYP3A4 reducing mRNa expression 2-5 fold is embedded in the main haplotype with negative LD versus all other variants in the proximal gene locus (wang et al. 2011a) . High minor allele frequency relative to extreme length of the haplotype blocks is a signature of positive selection; therefore, we expect more such variants to exist in the CYP gene family, with relevance to drug metabolism and treatment outcomes.
Over the very recent human history, we have been exposed to thousand of drugs that target proteins thought to play critical roles in disease, or defend the body against xenobiotics. exposure to these diverse chemicals has revealed underlying genetic variation that can cause failure to respond or elicit severe adverse drug reactions (Phillips et al. 2001) . In pharmacogenomics, odds ratios for genetic variants to affect treatment outcomes often are higher than observed for complex disease phenotypes, probably because drug targets reflect much more specific phenotypes (they refer to select biochemical or signaling pathways relevant to the pathophysiology of a subgroup of patients diagnosed with a complex disorder that potentially has multiple causes) (Sadee 2012) . These findings highlight the power of gene-environment interactions to reveal genetic variation. Nevertheless, the full genetic contribution to variable drug response is only partially understood-hence the missing heritability applies here as well. what is more important, drug target variants may not score significantly in GwaS related to disease risk, even if the variant has potentially robust effects on drug treatment outcomes [e.g., DRD2, DAT, HTR2A, MAOA (Table 2) ]. This has already been discussed with HMGCR, the target of statin medications widely used to treat heart disease, which appears as a GwaS hit for the intermediate phenotype of lipid levels but not the disease phenotype of coronary artery disease (Hindorff et al. 2014 ).
How to interpret GWAS data to address the 'missing heritability' issue?
Use of causative variants rather than marker SNPs Recent GwaS SNP panels cover a large portion of the human genome, including variants in multiple ethnic groups. Therefore, all but the least frequent variants should be accessible, either directly or by imputation; yet, a significant association of a SNP with a disease phenotype merely identifies a marker rather than specifying the causative variant. Surveying available evidence for candidate genes in coronary artery disease, we find hundreds of candidates; however, the causative variants remain unknown in the vast majority of cases. The wide-spread distribution of causative variants across a given gene locus renders their detection exceedingly difficult. without knowledge of the causative variants, interpretation of GwaS results is suboptimal. In particular, a significant association may not reveal whether the marker SNP signifies a loss or gain of function, or a distinct mechanism of the encoded RNa or protein. This challenge becomes more problematic when more than one functional variant affect a gene's activity.
To reveal the causative variants, the vast majority expected to be rSNPs and srSNPs, we have adopted a highly accurate approach measuring allelic RNa ratios in human target tissues (many regulatory variants are tissue selective), compared to allelic gDNa ratio of candidate genes (Fig. 4) (Johnson et al. 2008) . an imbalance between the two (allelic RNa expression imbalance, or aeI) detects a majority of rSNPs and srSNPs, and hence provides a comprehensive approach to discovery of regulatory variants. Importantly, this general approach is applicable to both protein-coding RNas and non-coding RNas; for the latter the function is directly associated with the RNa itself, providing unique insight into genetic RNa effects. Broadening this approach, use of SNP arrays and next-generation sequencing (RNaseq) enables genome-wide detection of aeI in coding and non-coding RNas Smith et al. 2013b) . One then scans the gene locus for SNPs that are heterozygous when aeI is present and homozygous if not. This ratio approach detects only cis-acting variants in that gene's locus even if the rSNPs can be at a distance of 100 kb or more (wang et al. 2014 ); however, trans-acting factors can determine the magnitude of the cis-effect, for example the interaction of a transcription factor with a variant enhancer site. This is exemplified by induction of the cytochrome P450 (CYP) family of enzymes. The effects of a promoter SNP may emerge only upon enzyme induction by other drugs or xenobiotics (Zanger and Schwab 2013) . while the allelic RNa ratio methodology discovers the majority of rSNPs and srSNP, one can miss specific events where the RNa with altered function is sequestered differentially by interactions with cellular components without changing the total RNa content of the cell. For example, mRNas engaged in active translation are enriched in polysomes compared to the total cells' mRNa content . srSNPs affording enhanced or reduced translation (NaT1 and OPRM1, respectively (wang et al. 2011b; Zhang et al. 2005) appear to assemble polysomes at distinct rates, a process that can be detected by allelic mRNa ratio analysis of polysomal RNa (R. Mascarenhas et al., unpublished) . If no variant can be detected, allele-specific or allele-selective epigenetic events must be considered such as imprinting, X-inactivation, or allele-selective silencing-an important process in cancer.
we have applied a candidate gene aeI approach to >200 genes, finding frequent regulatory variants in key genes related to disease relevant pathways. among those serving also as drug target, the incidence of frequent and robust aeI was highly enriched (Johnson et al. 2008) , with signatures of positive selection pressure. Table 2 documents the type of causative variants identified in these proteincoding genes, with different molecular mechanisms including enhancer and promoter activity, and RNa processing, splicing, turnover, sequestration, and translation. Strikingly, srSNPs are equally abundant compared to rSNPs; if extrapolated to non-coding genes, these results indicate that attention needs to be directed to the genetics of RNa biology. It is also striking that several genes harbor more than one frequent causative variant, often on distinct long haplotypes, for example in CETP, DAT, DRD2, and CHRNA5 (Table 2) . without understanding the interactions between these variants, an accurate assessment of the genetic impact is not feasible. From these results we conclude that numerous critical genes are likely to harbor frequent rSNPs and srSNPs, most of which remain to be discovered.
Conclusions
This review proposes a number of hypotheses that taken together have the potential to narrow the heritability gap found in complex phenotypes, related to both common diseases and drug therapies.
1. Large-scale association studies indicate that the vast majority of significantly associated variants resides outside the protein-coding exons, which comprise only 1.2 % of the human genome. 2. GwaS results have revealed numerous variants that are risk factors for disease but account for only a small portion of the genetic risk estimated from sibling studies. even with use of very large cohorts and the discovery of rare risk genes, the gap has not narrowed substantially. adding all risk factors in linear polygenic models appears to account for a substantial portion of heritable risk, but the underlying assumptions of additive effects may lead to incorrect estimates. (Smith et al. 2013b ) reveals instances of cis-acting regulatory variants, both rSNPs and srSNPs 3. One can divide variants by their function into cSNPs altering protein sequence, regulatory variants (rSNPs) that affect transcription, and those located in transcribed RNas, termed structural RNa variants (srSNPs) that affect RNa biology at many levels. srSNPs can alter the functions of protein-coding mRNas and of the numerous non-coding RNas. The latter are still poorly studied, but vast stretches of the human genome are transcribed into RNas (Djebali et al. 2012) ; hence, the potential for genetic influence of srSNPs is great. 4. Recent studies have shown that numerous rSNPs residing in regulatory DNa elements affect epigenetic DNa and chromatin marks (Heinz et al. 2013; Kilpinen et al. 2013; Mcvicker et al. 2013; Ziller et al. 2013 ) and thereby present a bridge between genetic and environmental factors that need to be considered jointly. 5. Rather than searching only for risk factors in GwaS analysis, one must also consider variants that are under positive selection. with strong evolutionary selection pressure on regulatory processes, these variants could wield a double-edged sword with unfavorable impact under certain conditions. However, such variants per se convey only marginal risk and therefore score poorly in GwaS, failing the burden of multiple hypotheses testing. 6. as epistasis appears to be a key element in evolution, we expect that those variants under positive selection pressure are most likely to reveal strong gene-gene interactions. Therefore, a search for epistatic interactions in GwaS should focus on variants preferably under positive selection pressures, in genes interacting with each other functionally at varying levels. Such interactions have substantial potential to narrow the heritability gap. 7. Genes under positive selection also tend to serve as drug targets that are central to physiological processes. Drug targets indeed appear to be enriched with carrying frequent rSNPs and srSNPs with a signature of positive selection. Possibly as a result of this relationship, drug response traits tend to carry a surprisingly high pharmacogenetics effect size-highlighting the strong influence of gene-environment interaction. Going one step further, one should consider dynamic gene-gene-environment interactions in predicting drug treatment outcomes, but only a few examples have been documented. 8. Lastly, a multi-stage disease model with a critical transition from wellness to 'off-well' and finally to disease dissects the heritability question into different categories: genes under positive selection may most strongly influence the wellness/off-well transition, from where the emergence of complex common diseases of advancing age is in part guided by deleterious variants detectable in GwaS.
This review discusses a new paradigm for understanding the 'missing heritability' in disease risk, focusing on genetic variants under evolutionary pressures relevant to providing reproductive advantage through maintaining wellness under varying environmental and social conditions. Understanding environmental stressors and their impact on recent human evolution may well be a key to advancing health care. Taking the view that drug therapy is but one example of new environmental stressors, variable drug response can also be accounted for by frequent variants in key genes, in addition to less frequent mutations with strong effect on disease and treatment outcomes, and specifically adverse drug effects. New therapies and preventions are likely to emerge with the insights gained from resolving outstanding genomics questions (Okada et al. 2014; Pierce et al. 2013) .
